共 310 条
[71]
Mease P(2022)Risankizumab treatment in psoriasis patients who failed anti-IL17: A 52-week real-life study Dermatol Ther 11 123-730
[72]
Foley P(2022)Efficacy of tildrakizumab for the treatment of difficult-to-treat areas: scalp, nail, palmoplantar and genital psoriasis J Clin Med 21 937-423
[73]
Gordon K(2022)Nail psoriasis improvement during tildrakizumab therapy: a real-life experience J Drugs Dermatol 24 719-178
[74]
Griffiths CEM(2013)Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study J Dermatolog Treat 223 420-732
[75]
Ohtsuki M(2011)Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study Dermatology 30 171-2535
[76]
Kubo H(2019)Comparison of NAPSI and N-NAIL for evaluation of fingernail psoriasis in patients with moderate-to-severe plaque psoriasis treated using ustekinumab J Dermatolog Treat 145 731-e1041
[77]
Morishima H(2009)Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists Arch Dermatol 14 2527-193
[78]
Goto R(2018)Tofacitinib for the treatment of psoriasis and psoriatic arthritis Expert Rev Clin Immunol 24 e1034-39
[79]
Zheng R(2010)Growth rate of human fingernails and toenails in healthy American young adults J Eur Acad Dermatol Venereol 8 183-undefined
[80]
Nakagawa H(2022)Racial, ethnic, and sex disparities in nail psoriasis clinical trials: a systematic review Skin Appendage Disord. 16 32-undefined